Incyte Receives FDA Approval for Pediatric Eczema Treatment

The US FDA has approved Incyte's eczema treatment for pediatric patients. Incyte is a biopharmaceutical company that develops therapies for cancer and inflammatory disorders. The company's revenue is primarily generated through product sales (85.3%), royalties (13.7%), and research and cooperation agreements (1%).

The U.S. Food and Drug Administration (FDA) has approved Incyte's topical JAK inhibitor, Opzelura, for the treatment of mild to moderate atopic dermatitis in children aged 2 through 11 years. This approval marks a significant milestone for Incyte, a biopharmaceutical company that specializes in developing therapies for cancer and inflammatory disorders.

The decision comes after a three-month delay, during which the FDA reassessed additional chemistry, manufacturing, and controls data submitted by Incyte. The approval is based on data from the Phase III TRuE-AD3 study, which demonstrated that Opzelura effectively cleared or almost cleared skin lesions in significantly more pediatric patients compared to a vehicle control. Opzelura is already approved for use in patients aged 12 and older with atopic dermatitis not adequately controlled by other topical prescription drugs.

Incyte's revenue is primarily generated through product sales (85.3%), royalties (13.7%), and research and cooperation agreements (1%). The approval of Opzelura for pediatric use is expected to expand the market for the drug and potentially increase Incyte's revenue streams.

In addition to atopic dermatitis, Opzelura is indicated for topical use in nonsegmental vitiligo. The product carries a boxed label warning about serious infections, malignancies, major adverse cardiovascular events, thrombosis, and a higher risk of all-cause death in patients treated with JAKs for inflammatory conditions.

The approval of Opzelura for pediatric eczema treatment is part of a busy month for the FDA, which is also reviewing applications for higher-dose formulations of Biogen's Spinraza, Scholar Rock's apitegromab, and Merck's subcutaneous Keytruda, among others. These decisions are expected to significantly impact the market and patient access to various therapies.